Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24719229 | 1.00 | SSTR4 (0.39) | SSTR4ENPEP | |
| SCHEMBL27204937 | 0.86 | NTSR2 (0.44) | — | |
| SCHEMBL27172528 | 0.86 | NTSR2 (0.44) | — | |
| SCHEMBL27172559 | 0.86 | NTSR2 (0.44) | — | |
| SCHEMBL27204885 | 0.86 | NTSR2 (0.44) | — | |
| SCHEMBL24719032 | 0.80 | ENPEP (0.34) | ENPEP | |
| SCHEMBL24718905 | 0.80 | ENPEP (0.34) | ENPEP | |
| SCHEMBL24720138 | 0.78 | SSTR4 (0.46) | SSTR4ENPEP | |
| SCHEMBL24718908 | 0.76 | ENPEP (0.44) | ENPEP | |
| SCHEMBL30078226 | 0.75 | MEN1 (0.40) | ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217922-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-07-04 | — | — | US | claimed |
| EP-4326742-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-02-28 | — | — | EP | claimed |
| WO-2022223805-A1 | MODULATORS OF SORTILIN ACTIVITY | INSUSENSE ApS (DK) | 2022-10-27 | — | — | WO | claimed |
| EP-4079748-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-10-26 | — | — | EP | claimed |
| US-20240217922-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-07-04 | — | — | US | disclosed |
| EP-4326742-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022223805-A1 | MODULATORS OF SORTILIN ACTIVITY | INSUSENSE ApS (DK) | 2022-10-27 | — | — | WO | disclosed |
| EP-4079748-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-10-26 | — | — | EP | disclosed |
| EP-4079748-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217922-A1 | MODULATORS OF SORTILIN ACTIVITY | SORT1, SCARB1, NPC1 | SSTR4 1841/4885ENPEP 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.